GSK Launches ReQuip XL R ropinirole Prolonged-release Tablets A New Once Daily Formulation For The Treatment Of Parkinson's Disease
GlaxoSmithKline (GSK) have announced the launch of a new treatment for Parkinson's disease (PD) in the UK. ReQuip XL (ropinirole prolonged-release tablets) is the UK's first and only once-daily non-ergot oral dopamine agonist available for the treatment of PD1, providing continuous delivery of ropinirole from a single daily dose2.
Neural Cell Transplants May Help Those With Parkinson's Disease
The current issue of Cell Transplantation (Vol. 17:4) features a number of publications by researchers seeking new ways to treat Parkinson's disease (PD), a neurological disease characterized by muscle rigidity, tremor and slowed physical movements related to insufficient levels of dopamine (DA) in the basal ganglia of the brain, by using primate models to examine the potential therapy role of transplanted cells.
Neurologists And Clinicians From Rush University Medical Center Present Latest Research Findings At The Movement Disorder Society Meeting
Leading neurologists and other clinicians from Rush University Medical Center are presenting new basic and clinical research findings at the Movement Disorder Society's 12th International Congress of Parkinson's Disease and Movement Disorders meeting in Chicago, June 22-26.
Buck Institute And Q Therapeutics Form Stem Cell Collaboration To Combat Parkinson's Disease
The Buck Institute for Age Research and Q Therapeutics, Inc. announced an agreement to collaborate on novel routes to combat Parkinson's disease. The Buck Institute and Q Therapeutics will use their expertise in differentiating stem cells to provide key cell types needed to study Parkinson's disease.
BrainStorm Cell Therapeutics NTF Cells Shows Significant Advantage In Pre-Clinical Study For Parkinson's Disease
BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced that in a pre-clinical study that was conducted with Tel Aviv University between February and May 2008, signs of impaired motor behavior in a rat model of Parkinson's improved following transplantation of BrainStorm's unique Neurotrophic Factor Cells (NTF).
Brainstorm Cell Therapeutics Chief Scientist, Dr. Daniel Offen, To Present Results From New Parkinson's Study At International Stem Cell Meeting
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced that Dr.
Adult Stem Cell Findings Offer New Hope For Parkinson's Cure
Research released today provides evidence that a cure for Parkinson's disease could lie just inside the nose of patients themselves.The Griffith University study published in the journal Stem Cells found that adult stem cells harvested from the noses of Parkinson's patients gave rise to dopamine-producing brain cells when transplanted into the brain of a rat.
BBVA Foundation International Study On Attitudes To Stem Cell Research
Unlike most scientific and technological advances, which tend to take their place silently in society, biotechnology often finds itself the center of public debate and regulatory attention, due partly to the moral issues posed by many of its applications.
23andMe And The Parkinson's Institute Announce Initiative To Advance Parkinson's Disease Research
23andMe, a privately-held personal genetics company, and The Parkinson's Institute and Clinical Center ("Parkinson's Institute") announced a research initiative under which Parkinson's Institute patients, with financial support from The Michael J. Fox Foundation, will enroll in the 23andMe Personal Genome Service™
EMEA Application For Nenad R lisuride Transdermal Patch And Subcutaneous Infusion For Parkinson's And Restless Leg Syndrome
Axxonis Pharma AG announces the submission of a marketing authorisation application to the European Medicines Agency (EMEA) for Nenad(R) (lisuride transdermal patch as add-on therapy for Parkinson's Disease and for Restless Legs Syndrome, and subcutaneous (sc) lisuride infusion fo.